Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,038
  • Shares Outstanding, K 5,430
  • Annual Sales, $ 580 K
  • Annual Income, $ -14,290 K
  • 60-Month Beta 1.03
  • Price/Sales 53.18
  • Price/Cash Flow N/A
  • Price/Book 1.26
Trade APRE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.78
  • Number of Estimates 2
  • High Estimate -0.75
  • Low Estimate -0.80
  • Prior Year -1.34
  • Growth Rate Est. (year over year) +41.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.32 +6.77%
on 04/10/24
6.88 -17.44%
on 03/19/24
-0.51 (-8.24%)
since 03/15/24
3-Month
4.82 +17.84%
on 01/26/24
8.85 -35.79%
on 03/01/24
-0.34 (-5.65%)
since 01/16/24
52-Week
2.78 +104.32%
on 07/07/23
8.85 -35.79%
on 03/01/24
+1.58 (+38.54%)
since 04/14/23

Most Recent Stories

More News
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 10.17 (-5.66%)
KA : 0.4133 (+21.56%)
APRE : 5.68 (-3.73%)
XFOR : 1.2700 (+1.60%)
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now

Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

APRE : 5.68 (-3.73%)
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APRE : 5.68 (-3.73%)
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies

Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.

SNY : 46.22 (-0.04%)
NVO : 124.00 (+0.08%)
ALLO : 3.51 (-1.13%)
APRE : 5.68 (-3.73%)
Biotech Bid Up Following First Patient Dosage

A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead...

APRE : 5.68 (-3.73%)
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 5.68 (-3.73%)
First Week of May 20th Options Trading For Aprea Therapeutics (APRE)

Investors in Aprea Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APRE options chain...

APRE : 5.68 (-3.73%)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 5.68 (-3.73%)
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

APRE : 5.68 (-3.73%)
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. ...

APRE : 5.68 (-3.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

3rd Resistance Point 6.35
2nd Resistance Point 6.18
1st Resistance Point 6.04
Last Price 5.68
1st Support Level 5.73
2nd Support Level 5.56
3rd Support Level 5.42

See More

52-Week High 8.85
Fibonacci 61.8% 6.53
Fibonacci 50% 5.81
Last Price 5.68
Fibonacci 38.2% 5.10
52-Week Low 2.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar